Establishment Labs Holdings (Nasdaq:ESTA) - Aktienkurs, Nachrichten und Analyse

ESTA Aktienübersicht

Establishment Labs Holdings Inc. ist ein Medizintechnikunternehmen, das medizinische Geräte für die ästhetische und rekonstruktive plastische Chirurgie herstellt und vertreibt.

Über das Unternehmen

ESTA grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	5/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	1/6
Dividenden	0/6

Belohnungen

47.3% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 69.45% pro Jahr

Risikoanalyse

Hat weniger als 1 Jahr Cash Runway

Die Aktionäre wurden im vergangenen Jahr verwässert

Establishment Labs Holdings Inc. Wettbewerber

STAAR Surgical

NasdaqGM:STAA

US$1.5b

Meridian Bioscience

NasdaqGS:VIVO

US$1.5b

Avanos Medical

NYSE:AVNS

US$1.0b

Bioventus

NasdaqGS:BVS

US$771.7m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Establishment Labs Holdings
Historische Aktienkurse
Aktueller Aktienkurs	US$41.59
52-Wochen-Hoch	US$60.12
52-Wochen-Tief	US$16.96
Beta	1.21
11 Monat Veränderung	0.24%
3 Monate Veränderung	-14.19%
1 Jahr Veränderung	-22.97%
33 Jahre Veränderung	-42.95%
5 Jahre Veränderung	98.62%
Veränderung seit IPO	68.04%

Aktuelle Nachrichten und Updates

Earnings Release: Here's Why Analysts Cut Their Establishment Labs Holdings Inc. (NASDAQ:ESTA) Price Target To US$59.86

Aug 11

Recent updates

Earnings Release: Here's Why Analysts Cut Their Establishment Labs Holdings Inc. (NASDAQ:ESTA) Price Target To US$59.86

Aug 11

Shareholders Should Be Pleased With Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) Price

Jul 23

Shareholders Should Be Pleased With Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) Price

Apr 17

Establishment Labs Holdings (NASDAQ:ESTA) Is Carrying A Fair Bit Of Debt

Dec 14

Establishment Labs drops 18% after new short report from Hindenburg Research

Oct 19

Establishment Labs: Flat Earnings, Return On Investment Keep Buyers At Bay

Sep 24

Establishment Labs Holdings (NASDAQ:ESTA) Is Carrying A Fair Bit Of Debt

Sep 04

Establishment Labs started at buy at B Riley on breast implants

Aug 24

Health Check: How Prudently Does Establishment Labs Holdings (NASDAQ:ESTA) Use Debt?

Feb 23

Is Establishment Labs Holdings (NASDAQ:ESTA) Using Debt Sensibly?

Sep 25

Aktionärsrenditen

	ESTA	US Medical Equipment	US Markt
7D	-9.2%	-1.4%	-4.4%
1Y	-23.0%	14.0%	19.1%

Rendite im Vergleich zur Industrie: ESTA unter dem Niveau der Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von 10.5% erzielte.

Rendite vs. Markt: ESTA hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 25.3 erzielte.

Preisvolatilität

Is ESTA's price volatile compared to industry and market?
ESTA volatility
ESTA Average Weekly Movement	8.7%
Medical Equipment Industry Average Movement	8.6%
Market Average Movement	6.3%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

Stabiler Aktienkurs: ESTADer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: ESTADie wöchentliche Volatilität (9%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2004	857	Juan Chacon Quiros	www.establishmentlabs.com

Establishment Labs Holdings Inc. ist ein Medizintechnikunternehmen, das medizinische Geräte für die ästhetische und rekonstruktive plastische Chirurgie herstellt und vertreibt. Das Unternehmen bietet hauptsächlich mit Silikongel gefüllte Brustimplantate unter der Marke Motiva Implants an. Darüber hinaus bietet es Motiva Ergonomix und Motiva Ergonomix2, runde, schwerkraftabhängige, weiche, mit Silikongel gefüllte Brustimplantate, sowie Motiva Flora Tissue Expander, einen Brustgewebeexpander, an.

Establishment Labs Holdings Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Establishment Labs Holdings im Vergleich zum Marktanteil des Unternehmens?
ESTA grundlegende Statistiken
Marktanteil	US$1.16b
Gewinn(TTM)	-US$83.20m
Umsatz(TTM)	US$151.35m

7.7x

Kurs-Umsatz-Verhältnis

-14.0x

Kurs-Gewinn-Verhältnis

Ist ESTA zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ESTA Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$151.35m
Kosten der Einnahmen	US$51.40m
Bruttogewinn	US$99.95m
Sonstige Ausgaben	US$183.15m
Umsatz	-US$83.20m

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-2.98
Bruttomarge	66.04%
Nettogewinnspanne	-54.97%
Schulden/Eigenkapital-Verhältnis	430.3%

Wie hat sich ESTA auf lange Sicht entwickelt?

Historische Performance und Vergleiche

ESTA Aktienübersicht

Belohnungen

Risikoanalyse

Establishment Labs Holdings Inc. Wettbewerber

NasdaqGM:STAA

US$1.5b

NasdaqGS:VIVO

US$1.5b

NYSE:AVNS

US$1.0b

NasdaqGS:BVS

US$771.7m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

No longer forecast to breakeven

Consensus EPS estimates fall by 25%

Earnings Release: Here's Why Analysts Cut Their Establishment Labs Holdings Inc. (NASDAQ:ESTA) Price Target To US$59.86

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2024

Establishment Labs Holdings Inc. to Report Q2, 2024 Results on Aug 06, 2024

Recent updates

No longer forecast to breakeven

Consensus EPS estimates fall by 25%

Earnings Release: Here's Why Analysts Cut Their Establishment Labs Holdings Inc. (NASDAQ:ESTA) Price Target To US$59.86

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2024

Establishment Labs Holdings Inc. to Report Q2, 2024 Results on Aug 06, 2024

Shareholders Should Be Pleased With Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) Price

Founder notifies of intention to sell stock

Insufficient new directors

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2024

Establishment Labs Holdings Inc. to Report Q1, 2024 Results on May 08, 2024

Establishment Labs Holdings Inc., Annual General Meeting, May 24, 2024

Establishment Labs Holdings Inc. announced delayed annual 10-K filing

Price target increased by 10% to US$52.86

Full year 2023 earnings: EPS exceeds analyst expectations

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2024

Establishment Labs Holdings Inc. to Report Q4, 2023 Results on Feb 28, 2024

Establishment Labs: Catalysts Supporting A Perky Outlook

Establishment Labs Holdings Inc. announced that it has received $49.999102 million in funding from a group of investors

Establishment Labs Holdings Inc. announced that it expects to receive $50 million in funding

Establishment Labs Holdings Inc. Announces First U.S. Commercial Procedure with Motiva Flora Tissue Expander

Forecast to breakeven in 2026

Is Establishment Labs Holdings (NASDAQ:ESTA) A Risky Investment?

Chairman of the Board recently bought US$110k worth of stock

Chairman of the Board exercised options to buy US$5.8m worth of stock.

Consensus revenue estimates fall by 18%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2023

New minor risk - Share price stability

Establishment Labs Holdings Inc. to Report Q3, 2023 Results on Nov 07, 2023

Establishment Labs Announces FDA Clearance of Motiva Flora Smoothsilk Tissue Expander

Price target decreased by 7.7% to US$89.38

Est Establishment Labs Holdings Inc. Announces Two-Year Mia Femtech Clinical Results and the Launch of Zen at 8th World Symposium on Ergonomic Implants

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2023

Is Establishment Labs Holdings (NASDAQ:ESTA) Using Too Much Debt?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Establishment Labs Holdings Inc. to Report Q2, 2023 Results on Aug 08, 2023

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.48 loss per share (vs US$0.24 loss in 1Q 2022)

Shareholders Should Be Pleased With Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) Price

Insider recently sold US$254k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Establishment Labs Holdings Inc. to Report Q4, 2022 Results on Feb 27, 2023

Establishment Labs Holdings Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Fiscal Year Ended December 31, 2022

Establishment Labs Holdings (NASDAQ:ESTA) Is Carrying A Fair Bit Of Debt

Establishment Labs Holdings Inc. Appoints Paul D. Rodio as Chief Operating Officer

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Establishment Labs Holdings Inc. Provides Earnings Guidance for the Year 2022

Establishment Labs Holdings Inc. to Report Q3, 2022 Results on Nov 07, 2022

Establishment Labs drops 18% after new short report from Hindenburg Research

Price target increased to US$97.40

Establishment Labs: Flat Earnings, Return On Investment Keep Buyers At Bay

Establishment Labs Holdings (NASDAQ:ESTA) Is Carrying A Fair Bit Of Debt

Establishment Labs started at buy at B Riley on breast implants

Establishment Labs Holdings Inc. Announces Executive Changes

Consensus forecasts updated

Second quarter 2022 earnings released: US$1.52 loss per share (vs US$0.22 loss in 2Q 2021)

No longer forecast to breakeven

Erträge & Einnahmen